Evidence map›Paper›PMID 38785213›Full record

ArticleCancer medicine2024

Effect of sustained measurable residue disease negativity and post-remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults.

Jiechen Yu, Yanrong Luo, Libing Wang, Tao Wang, Mingyu Ye, Jie Chen, Xiong Ni, Li Chen, Lei Gao, Jianmin Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiechen YuDepartment of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Yanrong LuoDepartment of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Libing WangDepartment of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Tao WangDepartment of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Mingyu YeDepartment of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Jie ChenDepartment of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Xiong NiDepartment of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Li ChenDepartment of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Lei GaoDepartment of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Jianmin YangDepartment of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.ORCID 0000-0002-6572-1541

Funding

Plan of GH145-13 GuHai GH145-13
6 · The paper itself

Abstract

backgroundTo explore the effects of monitoring measurable residual disease and post-remission treatment selection on the clinical outcomes of B-cell acute lymphoblastic leukemia (B-ALL) in adults.

methodsBetween September 2010 and January 2022, adult patients with B-ALL who received combination chemotherapy, with or without allogeneic hematopoietic stem cell transplantation (allo-HSCT), were included in the retrospective study, which was approved by the Ethics Committee and the observation of Declaration of Helsinki conditions.

resultsOne hundred and forty-three B-ALL patients achieved complete remission (CR) were included in the study, of whom 94 patients (65.7%) received allo-HSCT in first complete remission (CR1). Multivariate analysis showed that the most powerful factors affecting OS were transplantation (hazard ratio [HR] = 0.540, p = 0.037) and sustained measurable residue disease (MRD) negativity (HR = 0.508, p = 0.037). The subgroup analysis showed that the prognosis of the allo-HSCT group was better than that of the chemotherapy group, regardless of whether MRD was negative or positive after two courses of consolidation therapy. After consolidation therapy, the prognosis of patients with positive MRD remained significantly better in the allo-HSCT group than in the chemotherapy group. However, no significant difference was observed in the prognosis between the allo-HSCT and chemotherapy groups with negative MRD after consolidation therapy.

conclusionsB-ALL patients who achieve sustained MRD negativity during consolidation therapy have excellent long-term outcomes even without allo-HSCT. Allo-HSCT is associated with a significant benefit in terms of OS and DFS for patients who were with positive MRD during consolidation therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaRemission InductionAdolescentAdultFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTransplantation, HomologousTreatment OutcomeYoung Adultacute lymphoblastic leukemiaallogeneic hematopoietic stem cell transplantationmeasurable residual diseaseprognosis

Identifiers

PMID38785213
PMCPMC11117453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.